Instant Alert: CREDIT SUISSE: Everyone else on Wall Street is dead wrong about these 23 stocks

MANAGE SUBSCRIPTIONS   |   UNSUBSCRIBE   |   VIEW ONLINE   CREDIT SUISSE: Everyone else on Wall Street is dead wrong about these 23 stocks by Akin Oyedele on Mar 28, 2016, 7:42 AM Advertisement It's usually easier to move with the crowd, even on Wall Street.  But counterintuitive behavior is often what rakes in the big returns.  The equity research team at Credit Suisse recently published its latest list of contrarian stocks, or companies they think Wall Street is reading wrong. Andrew St Pierre and team wrote in the client note, "We screened our current US coverage universe to identify companies where our analysts’ views diverged from that of the Street, focusing on both rating as well as earnings projections. To further strengthen the list of stocks, we worked closely with the research analysts to select stories in which our conviction level is high. The result is a list of 11 Outperform-rated names and 12 Underperform-rated stocks." Here they are: First, the outperformers: Agios Pharmaceuticals Ticker: AGIO Target Price: $66 Company Description: Agios makes treatments for patients with cancer and rare genetic disorders of metabolism. Why Credit Suisse sees it differently: "We view AGIO as an Outperform based on the potential for AG-348/519 to gain approval for pyruvate kinase deficiency (PKD). We see the Street overtly discounting their market opportunity, and see the stock set up well into data at the European Hematology Association (EHA) conference in June. We view PKD as a disease area exhibiting high unmet medical need, and anticipate the market may be significantly larger than Street estimates based on the discovery of new causal mutations and currently low screening rates." Autodesk Ticker: ADSK Target Price: $100 Company Description: The company makes architecture and engineering software. Why Credit Suisse sees it differently: "We had previously expected Autodesk’s business model transition to result in meaningful long-term upside to revenue (at limited incremental cost) versus consensus estimates, driving "normalized" earnings power of at least $8.00 per share in FY2023. However, Autodesk's increased focus on expenses provides further operating leverage to the company's post-transition business model. As such, we now estimate post-transition earnings power of over $10.00 per share and FCF per share of nearly $11.00 in FY2023." See the rest of the story at Business Insider   Share the latest business news with your network: Email sent to:   |   Manage your email preferences   |   Unsubscribe Terms of Service   |   Privacy Policy Business Insider. 150 Fifth Avenue, New York, NY 10011